MUC16 and endometriosis: Throughout the treatment, a progressive decline in CA125 concentration was observed, becoming increasingly pronounced with prolonged treatment duration.This reduction in CA125, a biomarker often elevated in endometriosis, underscores the therapeutic impact of dienogest on disease activity [27].